Regenxbio Q3 net loss narrows 34% to $40.74 million
Bitget2026/11/05 12:22- Regenxbio’s third-quarter 2026 net loss narrowed 34% year over year to $40.74 million.
- Revenues fell 69% year over year to $9.16 million, primarily due to lower ZOLGENSMA royalties following U.S. patent expirations.
- The RGX-202 Duchenne therapy BLA submission remains on track for Q1 2027, with potential accelerated approval in the second half.
- Topline data from the pivotal ATMOSPHERE and ASCENT wet AMD trials are expected in Q4 2026.
- Cash, cash equivalents and marketable securities of $251 million at September 30, together with October settlement proceeds, should fund operations into late Q4 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Tesla (TSLA.US) drops over 10% in a week, but ARK keeps buying! Cathie Wood: This is the moment we've been waiting for
Despite the recent volatility in Tesla's stock price, ARK Invest founder Cathie Wood, known as the "Goddess of Wall Street," remains optimistic about the company.
U.S. stock futures fluctuate by $650 billions due to news related to Jensen Huang
Nikkei Average Index gains expand to 2.78%
Surprise! Japan intervened in the forex market three times this summer, selling a record 154 trillion yen in three days
Japan has confirmed that it intervened in the foreign exchange market three times this summer, buying yen to support the exchange rate, corroborating earlier market reports. This included the first joint intervention with the United States to support the yen in nearly thirty years.
Crypto prices
More
